Business of regenerative medicine: scalability and sustainability – the facility of the future


In the first part of RegMedNet’s expert panel on the business of regenerative medicine, learn more about the importance of considering scalability and sustainability when developing a cell therapy, its manufacture and eventual supply chain. Plus, the panelists share their pain points and discuss how the facility of the future might address them.

Chaired by Michael May, CCRM, this panel discussion focuses on the key business challenges within regenerative medicine. Joining Michael were four leading voices in regenerative medicine and cell therapy, from research to manufacture: Robert Preti (Hitachi Chemical Advanced Therapeutics Solutions, LLC), Robert Jones (Fisher Bioservices), Carolyn Yeago (Georgia Institute of Technology) and Qasim Rafiq (UCL).

The panel discussion took place in May 2018.

Learn more on RegMedNet’s website.

All other pages contact

For more information, please contact us.